Media Articles Related to Tenoretic (Atenolol / Chlorthalidone)
Breast cancer treatments could increase risk of developing osteoporosis or hypertension
Source: Health News from Medical News Today [2014.02.28]
Older women who have overcome breast cancer are likely to struggle with heart disease, osteoporosis and hypertension further on in their lives. Whether these conditions occur or not is influenced by the treatment that patients received to fight cancer, their overall weight and their age. Breast cancer survivors therefore should watch their weight and get regular exercise so that they can enjoy a high quality of life. These findings, by lead author Nadia Obi of the University Medical Center Hamburg-Eppendorf, who collaborated with the group of Prof.
10 of 11 new gene signals are likely drug targets for hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2014.02.24]
A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.
Opsumit approved by SwissMedic for pulmonary arterial hypertension
Source: Hypertension News From Medical News Today [2014.02.17]
Actelion Ltd has announced that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality.
Air pollution increases risk for hypertension in pregnant women
Source: Hypertension News From Medical News Today [2014.02.14]
Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study.
How the body regulates neuro-hormone has implications for hypertension, pain, stress, depression
Source: Anxiety / Stress News From Medical News Today [2014.02.12]
New research has revealed a previously unknown mechanism in the body which regulates a hormone that is crucial for motivation, stress responses and control of blood pressure, pain and appetite. The breakthrough could be used to design drugs to help fight health problems connected with these functions in the future.
Published Studies Related to Tenoretic (Atenolol / Chlorthalidone)
[A comparative study of atenolol (Tenormin) and the combined preparation atenolol/chlorthalidone (Tenoretic Mite) in essential hypertension. A randomized double-blind study from general practice] [1990.04.09]
Two hundred and ninety-two hypertensive patients from general practice who had previously been treated with a diuretic with insufficient effect participated in a randomised trial for a period of three months. A total of 115 patients completed treatment with 50 mg atenolol (Tanormin) and 121 were treated with the combined preparation consisting of 50 mg atenolol and 12.5 mg chlothalidone (Tenoretic Mite) while 56 patients defected from the trial.
Assessment of a fixed-dosage combination of atenolol and chlorthalidone (Tenoretic) in hypertensive Nigerians. [1990.03]
The antihypertensive effect of a fixed dosage combination of the cardioselective beta-adrenoceptor blocker, atenolol, and the oral thiazide-like diuretic, chlorthalidone (Tenoretic) was studied in 24 hypertensive Nigerians in a double-blind, cross-over comparison with three other treatments... The drugs were well tolerated.
Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison. [1988.11]
In a randomized, double-blind, parallel-group study of 31 patients with mild to moderate hypertension, we compared a placebo regimen with a regimen of atenolol and chlorthalidone (Tenoretic). The study, which lasted seven weeks, began with a single-blind two-week placebo lead-in period, followed by a four-week double-blind treatment phase, and concluded with a one-week single-blind placebo washout period.
[Photoallergy to Neotri and cross reaction to tenoretic--detection by systemic photoprovocation] [1988.01]
A patient is presented who suffered for 3 years from increasing photosensitivity with chronic eczematous lesions in sun-exposed areas...
Clinical Trials Related to Tenoretic (Atenolol / Chlorthalidone)
EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network [Not yet recruiting]
- Clinical equipoise exists with respect to the important question, "What is the best
initial diuretic for the treatment of Hypertension"? A pragmatic comparative
effectiveness research (CER) study comparing Chlorthalidone to Hydrochlorthiazide could
help inform decision making for this common problem.
- The investigators aim to harness both the power of bioinformatics (using web-based
data-capture and electronic health records) and of online media (through collaboration)
in order to facilitate such a CER in "usual-care" settings. This process may also
provide a foundation for testing a wealth of important clinical questions which
commonly arise in the delivery of contemporary healthcare and would otherwise be left
- To this end the investigators are developing a website, EBMtrialcentral, where eligible
physicians can go online and join their collaborative network. Physicians can then
enroll eligible patients in this study. These will include under-served urban patients.
Clinical information will be entered online (using a secure database housed at Johns
Hopkins), patient consent will be obtained electronically and treatment recommendations
will be randomly allocated to either 25mg daily of oral HCTZ or 12. 5mg daily of oral
Chlorthalidone. The investigators aim to increase to 50mg HCTZ and 25mg Chlorthalidone
over 8 weeks and compare their effects on BP measured with a 24 hour monitor.
- The investigators' primary hypothesis is that non-blinded, random, parallel allocation
of 12. 5mg daily Chlorthalidone (titrated to 25mg at 4 weeks) will demonstrate a
clinically meaningful â‰¥5mmHg improvement in BP control (as measured by change in BP
from baseline using 24hr ABPM) compared to 25mg daily HCTZ (titrated to 50mg at 4
weeks) in newly hypertensive patients followed in a usual-care clinic setting over 8
weeks. They will also analyze differences in side-effects or safety (serum
electrolytes) between these two medications.